Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
46.30
0.00 (0.00%)
At close: Dec 31, 2025, 4:00 PM EST
45.81
-0.49 (-1.06%)
Pre-market: Jan 2, 2026, 8:52 AM EST
Soleno Therapeutics Employees
Soleno Therapeutics had 92 employees as of December 31, 2024. The number of employees increased by 59 or 178.79% compared to the previous year.
Employees
92
Change (1Y)
59
Growth (1Y)
178.79%
Revenue / Employee
$1,072,554
Profits / Employee
-$852,717
Market Cap
2.49B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 92 | 59 | 178.79% |
| Dec 31, 2023 | 33 | 8 | 32.00% |
| Dec 31, 2022 | 25 | 5 | 25.00% |
| Dec 31, 2021 | 20 | 3 | 17.65% |
| Dec 31, 2020 | 17 | 5 | 41.67% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SLNO News
- 16 days ago - Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses - PRNewsWire
- 4 weeks ago - Soleno Therapeutics Announces the Passing of Board Member William G. Harris - GlobeNewsWire
- 7 weeks ago - Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKAT XR Starts, Discontinuations; Shares Down 26% – Hagens Berman - GlobeNewsWire
- 7 weeks ago - Soleno Therapeutics, Inc. Investigated by the Portnoy Law Firm - GlobeNewsWire
- 7 weeks ago - Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement - GlobeNewsWire
- 7 weeks ago - Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKATÔ XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman - PRNewsWire
- 2 months ago - Soleno Therapeutics, Inc. (SLNO) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR - GlobeNewsWire